SCHEMBL1526151

SCHEMBL1526151

O=C(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)NC1CCCCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 6/20 0.60
▸ THRA P10827 5/20 0.60
▸ PPARG P37231 5/20 0.60
▸ RXRA P19793 3/20 0.60
▸ ITGB3 P05106 1/20 0.60
▸ ITGAV P06756 1/20 0.60
▸ PCNA P12004 3/20 0.52
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ LMNA P02545 3/20 0.51
▸ ADORA3 P0DMS8 3/20 0.51
▸ PDE4D Q08499 3/20 0.51
▸ HSD17B10 Q99714 3/20 0.51
▸ CYP2C9 P11712 3/20 0.51
▸ EPHX2 P34913 3/20 0.51
▸ TTR P02766 2/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ HTR1A P08908 2/20 0.51
▸ HTR2B P41595 2/20 0.51
▸ PGR P06401 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17365412 0.95 THRB (0.55) THRBTHRAPPARGRXRAITGB3
SCHEMBL12837226 0.93 THRB (0.52) THRBTHRAPPARGRXRAITGB3
SCHEMBL14239795 0.91 THRB (0.50) THRBTHRAPPARGRXRAITGB3
SCHEMBL12837227 0.88 THRB (0.46) THRBTHRAPPARGRXRAITGB3
SCHEMBL16124428 0.87 PCNA (0.67) THRBTHRAPPARGRXRAPCNA
SCHEMBL1526155 0.86 EPHX2 (0.44) THRBTHRAPPARGRXRAITGB3
SCHEMBL1525943 0.83 EPHX2 (0.42) THRBTHRAPPARGRXRAITGB3
SCHEMBL12837224 0.82 EPHX2 (0.43) THRBTHRAPPARGRXRAITGB3
SCHEMBL12837222 0.80 EPHX2 (0.42) THRBTHRAPPARGRXRAITGB3
SCHEMBL1525946 0.76 THRB (0.73) THRBTHRAPPARGRXRAITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2442800-B1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS LLC (US) 2019-04-24 — — EP disclosed
EP-2442800-B1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS LLC (US) 2019-04-24 — — EP disclosed
US-9839614-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS, LLC (US) 2017-12-12 — — US disclosed
US-20160199309-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS, LLC 2016-07-14 — — US disclosed
US-9220788-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2015-12-29 — — US disclosed
US-9220788-B2 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof NANOPHARMACEUTICALS LLC (US) 2015-12-29 — — US disclosed
US-8802240-B2 Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells NANOPHARMACEUTICALS LLC (US) 2014-08-12 — — US disclosed
US-8802240-B2 Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells NANOPHARMACEUTICALS LLC (US) 2014-08-12 — — US disclosed
EP-2662079-A1 Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells Ordway Research Institute, Inc. (US) 2013-11-13 — — EP disclosed
EP-2662079-A1 Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells Ordway Research Institute, Inc. (US) 2013-11-13 — — EP disclosed
US-20120315320-A1 USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS NANOPHARMACEUTICALS LLC 2012-12-13 — — US disclosed
EP-2442800-A2 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF Ordway Research Institute, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010148007-A9 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF ORDWAY RESEARCH INSTITUTE, INC. (US) 2011-03-24 — — WO disclosed
US-20110052715-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF NANOPHARMACEUTICALS LLC 2011-03-03 — — US disclosed
WO-2010148007-A2 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF ORDWAY RESEARCH INSTITUTE, INC. (US) 2010-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160199309-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF TSHR, THRA, TRHR THRB 4/4885THRA 2/4885PPARG 145/4885
US-20120315320-A1 USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS TSHR, TPO, THRA THRB 5/4885THRA 3/4885PPARG 317/4885
US-20110052715-A1 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF TSHR, THRA, TRHR THRB 4/4885THRA 2/4885PPARG 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback